Table 2.
Univariate logistic regression analysis of factors associated with testing for hepatitis B virus serological markers prior to chemotherapy, but excluding those tested preoperatively (n = 3431)
| No. | Screening n (%) | P value | |
| Age (yr) | < 0.01 | ||
| ≤ 50 | 1215 | 240 (19.8) | |
| > 50 | 2216 | 345 (15.6) | |
| Sex | < 0.05 | ||
| Men | 2031 | 374 (18.4) | |
| Women | 1400 | 211 (15.1) | |
| Rituximab therapya | < 0.01 | ||
| Yes | 49 | 25 (51.0) | |
| No | 3382 | 560 (16.6) | |
| History of HBV infection | < 0.01 | ||
| Yes | 141 | 45 (31.9) | |
| No | 3290 | 540 (16.4) | |
| ALT and/or ASTb | < 0.01 | ||
| Abnormal | 205 | 128 (62.4) | |
| Normal | 3226 | 457 (14.2) | |
| Types of tumorc | < 0.01 | ||
| Hematological | 259 | 112 (43.2) | |
| Solid | 3172 | 473 (14.9) | < 0.05 |
| Liver cancer | 78 | 18 (23.1) | |
| Others | 3094 | 455 (14.7) |
a
P = 0.038 (OR: 1.96, 95%CI: 1.04-3.67);
b
P < 0.001 (OR: 10.88, 95%CI: 8.01-14.78);
c
P < 0.001 (OR: 4.17, 95%CI: 3.10-5.61). OR: Odds ratio; HBV: Hepatitis B virus; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase.